The top after-market NASDAQ gainers Friday were: Solazyme, Hansen Medical, Imperial Sugar, Cerus Corp, Complete Genomics and Cirrus Logic. The top after-market NASDAQ losers were: Anthera Pharmaceuticals, Southern Community Financial, Human Genome Sciences, Hi-Tech Pharmacal Co, Avanir Pharmaceuticals and GRAVITY Co.
Solazyme, Inc. (SZYM) stock climbed 5.65 percent to $13.66 in post market trading session after gaining more than 6 percent in regular trading.
Hansen Medical, Inc. (HNSN) stock surged 4.3 percent to $3.15 in aftermarket trading session. The company stock plunged nearly 5 percent in regular session.
Imperial Sugar Co. (IPSU) stock advanced 3.21 percent to $5.47 in aftermarket session.
Cerus Corp. (CERS) stock gained 2.68 percent to $3.83 in aftermarket trading session. The stock has a 52-week low of $1.92, a 52-week high of $4.09 and $179.41 million in market capitalization.
Complete Genomics, Inc. (GNOM) stock gained 2.01 percent to $3.56 in aftermarket trading session. The company stock slumped nearly 9 percent in regular session after Robert W. Baird lowered GNOM's fiscal 2012 and 2013 earnings estimates.
Cirrus Logic, Inc. (CRUS) stock gained 1.81 percent to $24.20 in aftermarket trading session. The stock has a 52-week low of $12.52, a 52-week high of $24.14 and $1.52 billion in market capitalization.
Anthera Pharmaceuticals, Inc. (ANTH) stock slumped 49.53 percent to $3.24 in post market trading session. The company announced that the VISTA-16 Data Safety Monitoring Board (DSMB) has recommended stopping the VISTA-16 clinical study due to a lack efficacy that could not be reasonably overcome in the remainder of the trial.
Southern Community Financial Co. (SCMFO) stock plunged 5.74 percent to $5.97 in aftermarket trading session.
Human Genome Sciences, Inc. (HGSI) stock plunged 4.5 percent to $7.86 in aftermarket trading session. The stock has a 52-week low of $6.51, a 52-week high of $30.15 and $1.64 billion in market capitalization.
Hi-Tech Pharmacal Co., Inc. (HITK) stock declined 3.05 percent to $3.05 percent to $36.83 in aftermarket trading session. The company reported fourth quarter net profit of $10.8 million or $0.79 per share compared to net profit of $10.1 million in the same quarter last year, but fell short of analysts' estimation of $0.83 per share.
Avanir Pharmaceuticals, Inc. (AVNR) stock fell 2.64 percent to $2.95 in post market trading session.
GRAVITY Co., Ltd. (GRVY) stock fell 2.21 percent to $2.66 in post market trading session after declining nearly 4 percent in regular session.